This review examines the differing arguments recent studies have made regarding blood pressure goals and cardiovascular risk.
Read More »Canagliflozin’s Renal and Cardiovascular Benefits in People with Heart Failure
CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure.
Read More »Mortality and Cardiovascular Benefits of SGLT-2 Inhibitors in Type 2 Diabetes
Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?
Read More »GIP and GLP-1 Receptor Agonist Tirzepatide Reduces CVD
Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.
Read More »Empagliflozin Receives Breakthrough Therapy Designation for HFpEF
The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).
Read More »An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.
Read More »The Human and Economic Burden of Diabetes and Its Comorbidities
Every comorbidity related to diabetes causes life expectancy to plummet and medical costs to soar.
Read More »Using Dapagliflozin for Reduction in Adverse Renal and CV Outcomes
Patients had significant reduction in urinary albumin-to-creatinine ratio (UACR) in the first six months of using dapagliflozin.
Read More »Don’t Forget our Patients with Type 1 Diabetes
Cardiovascular and renal disease burdens also occur in type 1 diabetes.
Read More »The Link Between Type 2 Diabetes and Heart Failure
A Mendelian Randomization found a correlation between type 2 diabetes and heart failure, utilizing genetic markers.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.